COPIKTRA Drug Patent Profile

When do Copiktra patents expire, and what generic alternatives are available?

Copiktra is a drug marketed by Secura and is included in one NDA. There are six patents protecting this drug.

This drug has two hundred and twenty-nine patent family members in thirty-nine countries.

The generic ingredient in COPIKTRA is duvelisib. One supplier is listed for this compound. Additional details are available on the duvelisib profile page.

DrugPatentWatch^® Generic Entry Outlook for Copiktra

Copiktra was eligible for patent challenges on September 24, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 24, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for COPIKTRA

International Patents:	229
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	69
Clinical Trials:	12
Drug Prices:	Drug price information for COPIKTRA
What excipients (inactive ingredients) are in COPIKTRA?	COPIKTRA excipients list
DailyMed Link:	COPIKTRA at DailyMed

See drug prices for COPIKTRA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for COPIKTRA

Constraining patent/regulatory exclusivity:

8,193,182

NDA:

211155

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for COPIKTRA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Phase 1/Phase 2
Secura Bio, Inc.	Early Phase 1
National Cancer Institute (NCI)	Early Phase 1

See all COPIKTRA clinical trials

US Patents and Regulatory Information for COPIKTRA

COPIKTRA is protected by eight US patents.

This potential generic entry date is based on patent 8,193,182.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Secura	COPIKTRA	duvelisib	CAPSULE;ORAL	211155-001	Sep 24, 2018		RX	Yes	No	9,840,505
Secura	COPIKTRA	duvelisib	CAPSULE;ORAL	211155-001	Sep 24, 2018		RX	Yes	No	RE46621		Y	Y
Secura	COPIKTRA	duvelisib	CAPSULE;ORAL	211155-001	Sep 24, 2018		RX	Yes	No	12,213,983
Secura	COPIKTRA	duvelisib	CAPSULE;ORAL	211155-001	Sep 24, 2018		RX	Yes	No	8,193,182			Y
Secura	COPIKTRA	duvelisib	CAPSULE;ORAL	211155-002	Sep 24, 2018		RX	Yes	No	8,193,182			Y

EU/EMA Drug Approvals for COPIKTRA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Secura Bio Limited	Copiktra	duvelisib	EMEA/H/C/005381Copiktra monotherapy is indicated for the treatment of adult patients with: Relapsed or refractory chronic lymphocytic leukaemia (CLL) after at least two prior therapies. Follicular lymphoma (FL) that is refractory to at least two prior  systemic therapies.	Authorised	no	no	no	2021-05-19

International Patents for COPIKTRA

When does loss-of-exclusivity occur for COPIKTRA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

European Patent Office

Finland

Hong Kong

Hungary

India

Israel

Japan

Lithuania

Luxembourg

Malaysia

Mexico

Netherlands

New Zealand

Norway

Philippines

Poland

Portugal

Russian Federation

San Marino

Singapore

Slovenia

South Africa

South Korea

Spain

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering COPIKTRA around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	084824
Argentina	117467
Australia	2012205669
Australia	2015258280
Brazil	112013017670

Supplementary Protection Certificates for COPIKTRA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2456444	301140	Netherlands		PRODUCT NAME: DUVELISIB; REGISTRATION NO/DATE: EU/1/21/1542 20210521
2456444	CA 2021 00045	Denmark		PRODUCT NAME: DUVELISIB; REG. NO/DATE: EU/1/21/1542 20210521
2456444	PA2021526	Lithuania		PRODUCT NAME: DUVELISIBAS; REGISTRATION NO/DATE: EU/1/21/1542 20210519
2456444	LUC00237	Luxembourg		PRODUCT NAME: DUVELISIB; AUTHORISATION NUMBER AND DATE: EU1/21/1542 20210521
2456444	122021000069	Germany		PRODUCT NAME: DUVELISIB; REGISTRATION NO/DATE: EU/1/21/1542 20210519

Copiktra (duvelisib) market dynamics and financial trajectory: exclusivity, competitive pressure, and revenue outlook

Last updated: June 28, 2026

Copiktra (duvelisib) has moved from a growth phase into a contraction driven by safety-driven label constraints, intense class competition in CLL/SLL and FL/WM, and the end of key patent and regulatory protections in parts of the market. Public financial reporting from its then-commercial owner (Secura Bio, later absorbed under its parent footprint) shows revenue peaks followed by sustained decline as prescriber adoption cooled and payor barriers tightened.

The net effect is a market trajectory defined less by pure incidence growth and more by (1) diminished willingness to use PI3K delta/gamma inhibitors, (2) substitution by BTK inhibitors and next-generation agents in CLL, and (3) competition from other PI3K programs that either cleared safety concerns or kept faster routes to preferred positioning.

What are the market dynamics driving Copiktra (duvelisib) performance in CLL/SLL and follicular lymphoma?

Direct answer: Copiktra’s market dynamics are dominated by safety and access constraints after label restrictions, plus rapid treatment-line substitution in CLL/SLL and FL/WM.

How label tightening changed demand and prescribing

Duvelisib (Copiktra) is a PI3K delta/gamma inhibitor used in relapsed/refractory settings that historically benefited from fast time-to-response and oral administration. Over time, real-world uptake faced three market levers:

• Risk-benefit re-framing by regulators and clinicians. Safety signals (notably infection risk and other serious adverse events) shifted its practical role toward carefully selected patients and settings with limited alternatives.
• Payor utilization management. Prior authorization, step edits, and tighter coverage criteria became common for agents in higher-risk categories, especially where competing therapies could be positioned earlier in treatment pathways.
• Guideline competition. BTK inhibitors, BCL2 inhibitors, and chemo-free combinations in CLL changed the sequencing calculus. In FL, treatment algorithms shifted toward agents with more favorable tolerability profiles and combination strategies.

What competing mechanisms displaced Copiktra

In both CLL/SLL and FL/WM, the competitive set is broad. The strongest displacing forces were:

• BTK inhibitors in CLL/SLL (fewer safety-driven discontinuations in routine practice versus PI3K inhibitors).
• BCL2 inhibition-based regimens and newer targeted combinations that improved depth and duration of response.
• Other PI3K pathway drugs and regimen strategies for lymphoma, with decision-making increasingly driven by tolerability and risk monitoring logistics.

How tendering and channel dynamics affect oncology specialty drugs

Specialty oncology drugs in the US are sensitive to:

• Specialty pharmacy channel strategies
• Manufacturer contracting terms tied to uptake
• Biosurveillance-driven formulary edits after safety communications
• Retrospective payer audits after claims patterns

For Copiktra, these mechanics generally reinforced contraction after initial growth, because demand became more conditional on patient selection and monitoring standards.

What is Copiktra’s FDA approval footprint and how did regulatory status affect sales?

Direct answer: Copiktra’s FDA positioning and subsequent safety-driven label evolution limited market expansion and narrowed the eligible patient pool.

Which indications shaped revenue

Copiktra’s commercial relevance in claims and coverage has been tied to US-labeled relapsed/refractory populations in:

• CLL/SLL
• Follicular lymphoma (FL) and related indications (including relapsed/refractory WM in earlier labeling context)

The practical sales impact comes from how payors interpret label constraints and how clinicians use PI3K inhibitors as later-line “option of last resort,” not as a default regimen.

What label language typically does to utilization

Even when an indication remains on-label, safety-related restrictions tend to:

• Reduce eligible prescriber sets
• Raise monitoring and discontinuation rates
• Increase reimbursement friction through payer and provider education

That translates into revenue compression even if the drug does not fully lose indication status immediately.

What is the patent and exclusivity landscape for Copiktra, and when do protections fall away?

Direct answer: Copiktra’s long-term market protection is linked to a combination of composition, method, and use patents plus regulatory exclusivity anchored to the duvelisib NDA/BLA date. As those expire across geographies, generic risk rises, especially once label constraints no longer provide “de facto protection.”

How exclusivity changes the revenue slope

In small-molecule oncology, revenue typically follows a pattern:

• Initial uptake driven by “no better options” and differentiation
• Peak during broad adoption
• Decline as competitors gain line-of-therapy preference
• Further compression around patent cliffs and label tightening
• Generic entry risk can accelerate decline even before actual launch if payers re-contract

Why patent strength matters less once payer friction rises

Even a partially protected product can see revenue drop faster than expected when:

• Safety communications reduce prescriber confidence
• Payers tighten access
• Guidelines shift sequencing

For Copiktra, both factors played a role, which steepened the post-peak curve.

Which companies compete with Copiktra and how does the competitive landscape affect pricing power?

Direct answer: Competitive pressure in CLL and lymphoma reduced pricing power, forced contracting concessions, and reduced share through treatment-line displacement.

Competitive displacement in CLL/SLL

Copiktra competed with:

• BTK inhibitors used broadly across relapsed settings
• BCL2 inhibitors
• Chemo-free combination regimens that improved outcomes and tolerability

This matters financially because CLL is a high-volume disease where treatment preference heavily influences market share.

Competitive displacement in FL/WM

In FL, choice architecture is shaped by:

• Use of immunochemotherapy alternatives and targeted therapies
• Combination strategies with improved duration
• Agents with established tolerability management programs

If a competitor offers similar efficacy with lower serious adverse event burden, payers and providers shift utilization.

Why oncology PI3K agents face structural pricing pressure

PI3K inhibitors operate in a segment where:

• Safety monitoring is resource-intensive
• Discontinuation rates are higher than many competing targeted oral options
• Total cost of care includes management of adverse events
• Claims data can trigger payer restrictions quickly

Those features reduce the ability to defend net price during contracting cycles.

How did Copiktra’s financial trajectory evolve and what do public market dynamics imply for revenue going forward?

Direct answer: The commercial path has been characterized by peak-then-decline as safety constraints and line-of-therapy displacement outweighed uptake growth, leaving revenue increasingly dependent on narrower subpopulations and continued payer access.

Revenue pattern consistent with post-peak PI3K uptake

Across oncology specialty drugs, the typical post-peak slope is:

• Volume contraction from reduced eligible use
• Net price decline from contracting leverage and audit pressure
• Lower reorder rates once formulary placement weakens
• Higher selling and support costs per net unit as access narrows

For Copiktra, this pattern aligns with market behavior described by industry observers and the company’s subsequent financial reporting trajectory during the contraction phase.

What drives near-term financial risk

The next steps that can materially change financial trajectory are:

• Further payer label restriction interpretation
• Uptake substitution in later lines as newer regimens move earlier in therapy
• Patent/regulatory events in jurisdictions where generic entry risk increases

What generic entry risks exist for Copiktra, and how do they affect investor expectations?

Direct answer: Generic entry risk increases as patent protections expire and as label constraints cease to support long-term utilization, prompting payers to re-optimize coverage.

Why generics can gain traction even before label loss

In constrained safety categories, payers frequently:

• Seek alternative sources for clinically acceptable substitutes
• Prefer lower acquisition cost when monitoring programs are standardized
• Shift coverage to products with more favorable total-cost trajectories

When net prices fall in response to contracting, the “last mile” of exclusivity becomes less valuable, accelerating revenue decline.

What is the Orange Book status of Copiktra, and how does it map to litigation risk?

Direct answer: Copiktra’s Orange Book-relevant protection set (listed patents and exclusivity codes) underpins generic “Paragraph IV” decisions and litigation exposure in the US. As protections narrow or expire, the probability of generic challenges rises.

How Paragraph IV timing typically affects Copiktra-like assets

In small-molecule oncology:

• Generic filings cluster near the end of listed patent term
• Litigation can delay launch but not always fully prevent delayed substitution
• Settlement patterns often lead to delayed entry with ongoing price pressure from authorized generics in some cases

What is the market-by-market exposure for Copiktra (US, EU, key ex-US markets)?

Direct answer: Market exposure is highest where:

• The drug has remaining labeled populations with clear unmet need
• Payor access remains stable
• Patent protection has not yet fully expired

EU and key ex-US markets may differ in timing because of local regulatory pathways, patent linkage mechanics, and parallel import rules.

Key takeaways

• Copiktra’s market dynamics are driven by safety-related label constraints and broad CLL/FL line-of-therapy displacement by other targeted oral agents.
• Revenue contraction has been reinforced by payer access friction and reduced eligible prescriber behavior, not only by competition on efficacy.
• Patent and exclusivity cliffs increase generic entry risk, but the sales curve can steepen earlier as payers and clinicians move to safer or more preferred regimens.
• Financial trajectory is most exposed to continued formulary narrowing and any additional shift in guideline sequencing away from PI3K inhibitors.

FAQs

1) How does duvelisib’s safety profile affect payer coverage and treatment sequencing?
It increases authorization scrutiny, monitoring requirements, and discontinuation risk, which pushes coverage toward preferred alternatives earlier in the relapsed pathway.

2) What treatment alternatives most directly reduce Copiktra share in CLL/SLL?
BTK inhibitors and other chemo-free targeted regimens that align better with sequencing preferences and tolerability expectations.

3) Do PI3K inhibitors face structural disadvantages versus BTK inhibitors in real-world oncology use?
Yes, in practice they face higher operational and monitoring burdens and can show less favorable discontinuation dynamics, which affects coverage and sustained demand.

4) What financial impact does a patent-expiration event typically have on specialty oncology revenue?
It can accelerate price concessions and demand forecasting changes; generic risk can pressure net revenue even before actual launch if payers re-contract.

5) How can settlement agreements alter generic entry risk for drugs like Copiktra?
Settlements can delay launch and define entry timing, but they often still shift net revenue toward lower-value share once payers prepare substitution scenarios.

References

1. FDA. Drug Label Information for COPIKTRA (duvelisib). U.S. Food and Drug Administration. (Accessed via FDA label database).
2. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (COPIKTRA entries and listed patents). U.S. Food and Drug Administration.
3. Company filings of Secura Bio (and successor corporate disclosures covering Copiktra commercialization and revenue trends). (Accessed via SEC EDGAR).

DrugChatter Q&A for COPIKTRA

What are the side effects of copiktra?
How does Copiktra treat CLL?